Unlocking the Potential: Amarin’s Reduce-It Data at ACC 23 WCC Demonstrates the Life-Saving Benefits of Vascepa/Vazkepa in High-Risk Patients with Recent Acute Coronary Syndrome Events

Post-Hoc Analysis Shows IPE Significantly Reduced Risk of First, Total Ischemic Events by 37% and 36% Respectively in Patients with Recent ACS Without Increased Bleeding Analysis Builds on Consistently Demonstrated Positive Outcomes for VASCEPA/VAZKEPA Across Sub-Populations in REDUCE-IT, Including in Patients with Prior Myocardial Infarction (MI), Prior Revascularization, Prior Peripheral Arterial Disease (PAD) and Diabetes…

Read More

Breaking News: Hillman Successfully Completes Secondary Offering of Common Stock with Full Exercise of Overallotment Option by Underwriters

Hillman Closes Secondary Offering of Common Stock by Selling Stockholders; Underwriters… CINCINNATI, March 03, 2023 (GLOBE NEWSWIRE) — Hillman Solutions Corp. (Nasdaq: HLMN) (the “Company” or “Hillman”), a leading provider of hardware products and merchandising solutions, today announced the closing of the previously announced underwritten public offering of shares of the Company’s common stock (the…

Read More

Bronstein, Gewirtz & Grossman LLC Alerts ALICO Inc. (ALCO) Investors of Class Action Lawsuit: How to Take Action

Bronstein, Gewirtz & Grossman, LLC Notifies Alico, Inc. (ALCO) Investors of Class Action and to Actively Participate Stay Informed on the Latest Legal Developments New York, March 03, 2023 (GLOBE NEWSWIRE) – Attorney Advertising–Bronstein, Gewirtz & Grossman, LLC notifies investors that a class action lawsuit has been filed against Alico, Inc. (“Alico” or “the Company”)…

Read More

Revolutionizing Insulin Delivery: The Emergence of Smart Pens and Needles Driving Demand in the Market, Projected to Surpass $33.1 Billion by 2033

Insulin Delivery Devices Demand Fueled by Emergence of ‘Smart’ Pens & Needles, Market to Outstrip US$ 33.1 Billion by 2033 Rockville, March 03, 2023 (GLOBE NEWSWIRE) — The global insulin delivery devices market is poised to expand at 7% CAGR during the forecast period (2023 to 2033). Worldwide insulin delivery device sales are expected to…

Read More